IDRA Idera Pharmaceuticals Inc.

1.87
-0.03  -2%
Previous Close 1.9
Open 1.92
Price To Book 1.44
Market Cap 53,990,689
Shares 28,872,026
Volume 100,884
Short Ratio
Av. Daily Volume 248,691
Stock charts supplied by TradingView

NewsSee all news

  1. Idera Pharmaceuticals Provides 2020 Update and Outlook

    EXTON, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and providing a corporate

  2. Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million

    EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional

  3. Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    EXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of

  4. Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

    EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No.

  5. Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

    EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 final data due 2Q 2020.
Tilsotolimod + ipilimumab - ILLUMINATE 204
Cancer - melanoma
Development suspended - September 2016.
IMO-8400
Waldenström’s Macroglobulinemia
Development suspended - September 2016.
IMO-8400
Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 data released June 12, 2018 - primary endpoint not met.
IMO-8400
Dermatomyositis
Phase 1b data at AACR April 2019 noted 45% disease control rate.
Tilsotolimod - ILLUMINATE 101
Solid tumors
Phase 3 data due 4Q 2020/ 1Q 2021.
Tilsotolimod (IMO-2125) + ipilimumab - ILLUMINATE 301
Melanoma
Phase 2 interim data due 2Q 2020.
Tilsotolimod + nivolumab and ipilimumab - ILLUMINATE 206
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Latest News

  1. Idera Pharmaceuticals Provides 2020 Update and Outlook

    EXTON, Pa., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or Idera or the Company, today is providing an update on its tilsotolimod clinical development program and providing a corporate

  2. Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million

    EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional

  3. Idera Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2019 Financial Results

    EXTON, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of

  4. Idera Pharmaceuticals Announces New U.S. Patent For Tilsotolimod Through September 2037

    EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, 2019 U.S. Patent No.

  5. Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors

    EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, a toll-like receptor 9 (TLR9)

  6. Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie

    EXTON, Pa., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) announced today that they have entered into an immuno-oncology clinical research collaboration with AbbVie, a global,

  7. Idera Pharmaceuticals to Present at the Baird 2019 Global Healthcare Conference

    EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wednesday, September 4, 2019 at